Glymphatic System

The glymphatic system is a macroscopic waste clearance system that utilizes a unique system of perivascular tunnels, formed by astroglial cells, to promote efficient elimination of soluble proteins and metabolites from the central nervous system. ^[1] It is a brain-wide network supporting cerebrospinal fluid and interstitial fluid exchange that is essential for removing metabolic waste from the brain. ^[2]

The glymphatic system enables bulk movement of cerebrospinal fluid from the subarachnoid space along periarterial spaces, where it mixes with interstitial fluid within the parenchyma before ultimately exiting via perivenous spaces. ^[3] Influx of cerebrospinal fluid depends upon the expression and perivascular localization of the astroglial water channel aquaporin-4, and a meta-analysis demonstrated a significant decrease in tracer transport in Aqp4 knock-out mice and rats compared to controls. ^[4] Glymphatic clearance of potentially harmful metabolic or protein waste products such as amyloid-beta is primarily active during sleep, when its physiological drivers, the cardiac cycle, respiration, and slow vasomotion, together efficiently propel cerebrospinal fluid inflow along periarterial spaces. ^[5] During sleep the major neuromodulators exhibit synchronized fluctuations that are phase-coupled to cerebrospinal fluid flow and drive slow vasomotion, providing the mechanical force that supports glymphatic clearance of metabolic waste. ^[6]

The glymphatic system degrades with age, suggesting a causal relationship between sleep disturbance and symptomatic progression in the neurodegenerative dementias, for which glymphatic failure may constitute a therapeutically targetable final common pathway. ^[7] Discovering novel strategies for optimizing and maintaining efficient brain waste clearance across the lifespan may prove important for preventing cognitive decline and sustaining healthy aging. ^[8] In rodents the glymphatic pathway is predominantly active during sleep, and altered aquaporin-4 expression with glymphatic dysfunction has been shown in animal models of traumatic brain injury, Alzheimer's disease, and stroke. ^[9]

Glymphatic dysfunction promotes amyloid-beta and tau accumulation, neuroinflammation, and vascular impairment, and emerging interventions including aquaporin-4 modulation and meningeal lymphatic regeneration are being explored for their potential to shift Alzheimer's therapeutics from symptom management to disease modification. ^[10] Approximately 10% of dementia patients have idiopathic normal pressure hydrocephalus, and human studies have implicated impaired glymphatic function in both this condition and Alzheimer's disease, so investigation of glymphatic biology could lead to new strategies to restore homeostatic brain metabolism and cerebrospinal fluid dynamics. ^[11] A causal role for glymphatic dysfunction in Alzheimer's disease has not yet been established in humans, and the absence of clinically suitable imaging approaches to measuring glymphatic exchange is an obstacle to developing and evaluating therapeutics to modulate glymphatic function. ^[12]